Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

1.650 -0.070 (-4.07%)

Official Closing Price Updated: 6:30 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

June 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

June 09, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can Fite Biofarma: Q1 Earnings Insights ↗

May 26, 2022

Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement.

Via Benzinga

CAN-FITE ISSUES LETTER TO SHAREHOLDERS ↗

January 05, 2022

Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,...

Via Benzinga

Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2 ↗

May 26, 2022

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1...

Via Benzinga

Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

May 26, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Granted Key NASH Patent in Israel

May 16, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

May 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis? ↗

April 12, 2022

Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug

April 05, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

March 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update ↗

March 24, 2022

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced

Via Benzinga

This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants ↗

March 24, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

March 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

March 14, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX ↗

March 11, 2022

Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)...

Via Benzinga

Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study ↗

March 08, 2022

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson...

Via Benzinga

Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor? ↗

February 03, 2022

Photo by Diana Polekhina on Unsplash

Via Benzinga

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

January 31, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

A New Oral Therapy for Psoriasis Could Be Coming Soon ↗

January 24, 2022

Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice...

Via Benzinga

Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows ↗

January 13, 2022

Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO ↗

January 13, 2022

Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:...

Via Benzinga

Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

January 13, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference ↗

January 10, 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs...

Via Benzinga

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

January 10, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Issues Letter to Shareholders

January 05, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS ↗

January 03, 2022

Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a...

Via Benzinga

45 Biggest Movers From Yesterday ↗

December 30, 2021

Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME...

Via Benzinga

26 Stocks Moving In Wednesday's Mid-Day Session ↗

December 29, 2021

Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.